Pre-clinical results on naproxcinod were presented at the MDA Scientific Conference in a poster entitled “Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in mdx mouse model of dystrophy." The effects of naproxcinod were investigated on skeletal and cardiac muscle function in mdx mice. The results of the study suggest that naproxcinod may have potential as a safe therapeutic option.